(Reuters) - Shares in the Massachusetts-based maker of multiple
sclerosis drugs Tysabri and Avonex rose $1.12, or 2.4 percent,
to close at $48.13 in heavy Nasdaq trade on Wednesday.
Biogen call options, granting the right to buy the
company's shares, were also on investors' radar screens as they
positioned for a potential move in the underlying stock.
Read more at Reuters.com Mergers News
sclerosis drugs Tysabri and Avonex rose $1.12, or 2.4 percent,
to close at $48.13 in heavy Nasdaq trade on Wednesday.
Biogen call options, granting the right to buy the
company's shares, were also on investors' radar screens as they
positioned for a potential move in the underlying stock.
Read more at Reuters.com Mergers News
No comments:
Post a Comment